FDA Approves Bepirovirsen: The First Antisense Oligonucleotide Therapy for Chronic Hepatitis B
The U.S. Food and Drug Administration approved bepirovirsen, sold as Hibsago, on October 20, 2026 — the first antisense oligonucleotide therapy authorized for chronic hepatitis B, a disease where standard drugs have almost never allowed patients to stop treatment, Raportul de Gardă reported.
Key Clinical Takeaways:
- The FDA approved bepirovirsen (Hibsago) on October 20, 2026 — the first therapy for chronic hepatitis B that targets viral RNA directly.
- About 19% of eligible patients in two Phase III trials kept the virus’s surface antigen undetectable for at least 24 weeks after stopping all antiviral therapy; no placebo patients did.
- Current standard drugs suppress replication but rarely eliminate the viral reservoir, so most patients stay on treatment for life.
What the approval changes for patients
Unlike conventional antivirals, which block replication of the hepatitis B virus (HBV), bepirovirsen acts directly on viral RNA. It reduces production of viral proteins and, in a share of patients, opens the possibility of keeping the infection under control after treatment stops, according to Raportul de Gardă’s report. That is a shift from the current model of care, in which therapy is typically indefinite.
Raportul de Gardă reported the same approval, framing it as a new stage in the treatment of chronic hepatitis B. The two outlets agree on the core facts: the drug, the date, the mechanism and the trial basis.
The trials behind the decision
The FDA’s decision rests on two randomized Phase III studies, B-Well 1 and B-Well 2, published in the New England Journal of Medicine, according to Radio România Cultural. After treatment with bepirovirsen, roughly 19% of eligible patients maintained undetectable levels of the virus’s surface antigen (HBsAg) and control of viral replication for at least 24 weeks after stopping all antiviral therapy, Raportul de Gardă reported. In the placebo group, that figure was zero.
Functional control of HBsAg — the marker that defines durable off-treatment response — has been the field’s hardest endpoint. Under standard therapy, loss of HBsAg remains rare, which is why most patients require long-term treatment.

Why existing drugs fall short
Standard of care today relies on nucleoside and nucleotide analogues such as tenofovir and entecavir. These inhibit the viral reverse transcriptase, preventing formation of viral DNA and efficiently suppressing replication. They can slow liver disease progression, reduce complications and improve survival.
But they do not usually eliminate the persistent viral reservoir inside hepatocytes, and they have limited effect on production of viral antigens, per Raportul de Gardă. One central difficulty is cccDNA — covalently closed circular DNA — a stable structure in the nucleus of liver cells that keeps transcribing viral RNA.
Fragments of HBV DNA integrated into the hepatocyte genome can also keep producing surface antigen. Even when replication is well controlled, viral genetic material continues to sustain the proteins tied to persistent infection.
How bepirovirsen works
Bepirovirsen is an antisense oligonucleotide: a short synthetic sequence of nucleic acids designed to recognize, by complementarity, a specific region of HBV RNA. Once bound, the drug recruits the cellular enzyme RNase H1, which degrades the targeted RNA. That prevents the RNA from being used to make viral proteins and contributes to reduced replication, Raportul de Gardă explained.
The mechanism allows reduction of multiple viral transcripts, including those driving antigen production — the difference that separates it from reverse-transcriptase inhibitors and underlies the off-treatment responses seen in the trials.
The scale of the disease
Chronic hepatitis B remains a major public health problem. According to the World Health Organization, approximately 240 million people were living with chronic HBV infection in 2024, and the disease caused about 1.1 million deaths, mainly through cirrhosis and hepatocellular carcinoma.
Prevention and treatment of HBV also feature in the fifth edition of the European Code Against Cancer, launched in 2026, which includes recommendations on HBV vaccination and on testing and treating viral hepatitis infections as part of reducing liver cancer risk, Raportul de Gardă reported, according to Raportuldegarda.
Where the coverage differs
Raportul de Gardă carried the full clinical detail — mechanism, trial names, endpoint figures — as part of its Știința 360 program with dr. Marius Geantă, președintele InoMed, Centrul pentru Inovație în Medicină.
What stays open
The 19% off-treatment response rate means roughly four in five eligible patients did not achieve durable control after stopping therapy in the trials, so the approval does not end long-term treatment for most. Raportul de Gardă’s reporting does not address durability beyond 24 weeks, response predictors, or safety findings in detail.
Patients on tenofovir or entecavir considering whether this approach applies to them would need evaluation. eligibility criteria from the trials, liver disease stage and current viral markers all shape who is a candidate.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.